Hedeker Wealth LLC Has $9.73 Million Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Hedeker Wealth LLC boosted its Eli Lilly stake by 375.9% in Q4 to 9,052 shares worth $9.73 million, making LLY 2.0% of its holdings and its 14th-largest position.
• Eli Lilly beat estimates with Q4 revenue of $19.29 billion and EPS of $7.54 (revenue +42.6% YoY), and set FY2026 guidance of 33.50–35.00 EPS.
• Analysts maintain a consensus "Moderate Buy" on LLY with an average target of $1,224.59, reflecting mostly positive ratings (2 Strong Buy, 23 Buy, 4 Hold, 1 Sell) and several raised price targets.

Hedeker Wealth LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 375.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,052 shares of the company's stock after acquiring an additional 7,150 shares during the period. Eli Lilly and Company comprises 2.0% of Hedeker Wealth LLC's holdings, making the stock its 14th largest holding. Hedeker Wealth LLC's holdings in Eli Lilly and Company were worth $9,728,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in LLY. Exencial Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 189.6% in the 3rd quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after purchasing an additional 11,396 shares during the last quarter. Rede Wealth LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at approximately $487,000. Cidel Asset Management Inc. lifted its stake in Eli Lilly and Company by 26.5% in the 3rd quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock valued at $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Spire Wealth Management lifted its stake in Eli Lilly and Company by 2.2% in the 4th quarter. Spire Wealth Management now owns 27,719 shares of the company's stock valued at $29,789,000 after purchasing an additional 592 shares during the last quarter. Finally, Coldstream Capital Management Inc. lifted its stake in Eli Lilly and Company by 25.6% in the 3rd quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock valued at $32,365,000 after purchasing an additional 8,659 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Jefferies Financial Group set a $1,300.00 price objective on shares of Eli Lilly and Company and gave the company a "buy" rating in a research note on Friday, March 13th. Guggenheim dropped their price objective on shares of Eli Lilly and Company from $1,168.00 to $1,163.00 and set a "buy" rating for the company in a research note on Monday, March 30th. Zacks Research cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. Finally, Cantor Fitzgerald upped their price target on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,224.59.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly received another buy rating tied to its newly launched obesity pill, which analysts expect to be a global bestseller — this supports revenue upside from weight‑loss therapies. Eli Lilly Stock (LLY) Gets Another Buy Rating as Its Obesity Pill Hits the Market
• Positive Sentiment: Lilly agreed to acquire CrossBridge Bio for up to $300M, adding preclinical ADC technology to bolster oncology pipeline optionality and long‑term growth prospects. Lilly to acquire CrossBridge Bio for up to $300m
• Positive Sentiment: Distribution and access expand as digital care platform Shed adds Foundayo™ (Lilly’s oral GLP‑1 for weight management), which can help broaden patient uptake beyond specialty clinics. Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide
• Positive Sentiment: Lilly is licensing its TuneLab AI platform to partners (e.g., Vasa Therapeutics), highlighting additional revenue streams and R&D leverage from proprietary AI tools. Vasa Therapeutics Partners with Lilly TuneLab to Power AI/ML-Driven CAMKII Inhibitor Platform
• Neutral Sentiment: Macro/valuation commentary remains mixed — some bullish, long‑term price targets (e.g., Forbes piece on LLY to $2,000) reflect confidence in blockbuster drugs but are speculative. LLY Stock To $2,000?
• Neutral Sentiment: Market reports note the stock is down today despite broader market gains — a short‑term price action update for traders. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: Competitive risk is rising: Novo Nordisk’s new partnership with OpenAI to accelerate drug discovery reinforces its capability to close gaps in the weight‑loss market and may pressure Lilly’s market share and investor sentiment. NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up

Eli Lilly and Company Stock Down 1.8%

Shares of NYSE LLY opened at $905.73 on Thursday. The firm has a market cap of $855.75 billion, a PE ratio of 39.47, a P/E/G ratio of 1.07 and a beta of 0.51. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company's fifty day simple moving average is $976.09 and its 200 day simple moving average is $979.89. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. Eli Lilly and Company's revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.